Asthma is a chronic disease of airways with an underlying inflammatorycomponent. Its prevalence has increased dramatically in recentyears. Although inhaled steroids are the cornerstone in long term therapyof asthma, poor patient compliance and the systemic side effectsespecially when high doses are required in long term control of thedisease are still a major concern.So, as a result of the increased understanding of the pathophysiologyof asthma, new classes of medications have been introduced during thelast few years such as leukotriene antagonists and anti-IgE antibody. Inthis study we discussed a number of those new medications and theirplace in the treatment guidelines of asthma.